Matthieu Schmitt

Indaver NV provides waste management services. It offers management of hazardous, household and industrial waste. The firm's activities include treatment and disposal of special waste, landfill and other services. Indaver was founded in 1985 and is headquartered in Mechelen, Belgium.

BNP Paribas Fortis Private Equity Belgium NV is a Private Equity/Venture Capital firm, a subsidiary of BNP Paribas Fortis SA/NV founded in 1981. BNP Paribas Fortis Private Equity Belgium NV is headquartered in Brussels.

Sopartec SA is the investment and technology valorization arm of Université Catholique de Louvain (UCL) and was founded in 1942. Sopartec SA is headquartered in Louvain-la-Neuve, Belgium.

Societe de Developpement et de Participation du Brabant Wallon SA (Invest.BW) is a private equity and venture capital firm founded in 1987. Invest.BW SA is headquartered in Louvain-la-Neuve.

Gimv (Private Equity) is a Private Equity firm, a subsidiary of Gimv NV (XB: GIMB) founded in 1980. Gimv (Private Equity) is headquartered in Antwerp, Belgium.

CISSOID SA manufactures industrial voltage regulators, oscillators and related electrical equipment. It offers temperature semiconductor solutions, delivering standard products and custom solutions for power management, power conversion and signal conditioning in extreme temperature and harsh environments. The firm's products include enable energy, weight and cost savings in lighter, cooling-free and more compact electronic systems. The company was founded by Pierre Delatte, Demeus Laurent, Vincent Dessard and Denis Flandre in 2000 and is headquartered in Mont-Saint-Guibert, Belgium.

Xylowatt SA designs, develops and builds gasification reactors for energy conversion from biomass and waste products. It offers NOTAR gasification reactor that produces syngas; and expert services. The company’s products convert energy from clean wood waste, contaminated wood, creosoted wood, radionuclides contaminated wood, agro residues, and sewage sludge. Its product is used in CHP and industrial applications. The company was founded in 2001 and it is headquartered in Charleroi, Belgium.

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.

Fortino Capital Partners NV is a venture capital and private equity firm founded in 2013 by Duco W. Sickinghe and Renaat Berckmoes. The firm is headquartered in Antwerp with additional office in Amsterdam.

Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium.

Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation.